© by the American Society for Pharmacology and Experimental Therapeutics
Pharmacological Reviews, 10.1124/pr.108.00372
International Union of Pharmacology: Status of the Calcitonin Gene-Related Peptide Subtype 2 Receptor
Debbie L. Hay 1,
David R. Poyner 1*,
Remi Quirion 1
1 School of Biological Sciences, University of Auckland, Auckland, New Zealand (D.L.H.); School of Life and Health Sciences, Aston University, Birmingham, United Kingdom (D.R.P.); and Department of Psychiatry, Douglas Hospital Research Centre, McGill University, Montréal, Québec, Canada (R.Q.)
* To whom correspondence should be addressed. E-mail: d.r.poyner{at}aston.ac.uk.
 |
Abstract |
|---|
Historically, calcitonin gene-related peptide (CGRP) receptors have been divided into two classes, CGRP1 and CGRP2. After the cloning of calcitonin receptor-like receptor (CLR) and receptor activity-modifying proteins (RAMPs), it became clear that the CGRP1 receptor was a complex between CLR and RAMP1. It is now apparent that the CGRP2 receptor phenotype is the result of CGRP acting at receptors for amylin and adrenomedullin. Accordingly, the term "CGRP2" receptor should no longer be used, and the "CGRP1" receptor should be known as the "CGRP" receptor.
